NFKB1 and rheumatoid arthritis: Research indicates that IGU can selectively inhibit cyclooxygenase-2 (COX-2) and NF-κB to alleviate inflammatory responses, particularly in cases of primary or secondary drug resistance in RA (Deng et al., 2022).